Publications & Presentations

The Cancer Support Community is continually working on new research in various topics areas that are important to people impacted by cancer. Below please find access to reports, posters and presentations of our research. Many of these publications and presentations have been presented at prominent cancer focused conferences and meetings, including the American Society of Clinical Oncology (ASCO) annual meeting and the National Comprehensive Cancer Network Annual Conference.

 

CancerSupportSourceTM‐Caregiver is a distress screening, referral, and support program designed to identify the unmet needs of cancer caregivers and link caregivers to desired resources and support. This study refined and finalized the CancerSupportSource‐Caregiver screening measure and examined its psychometric properties.

Psycho-Oncology Journal of Psychological, Social, and Behavioral Dimensions of Cancer
2023

Biomarker testing (BT) in oncology is rapidly becoming the standard of care across cancer types. There is an established relationship between BT and subsequent prognosis, as well as patient-reported outcomes; thus, the barriers and facilitators for BT are essential to understand. This study investigated the utilization of BT among people diagnosed with cancer and the most frequently experienced BT problems, as well as the person and systems-level factors associated with BT problems.

ASCO Quality Care Symposium
2022

In blood cancers like lymphoma, patients often feel their cancer is invisible to others, and may have less contact with the healthcare team during periods of prolonged remission. Further, lymphoma patients experience levels of distress, anxiety, and depression that can impact participation in treatment or hinder treatment decision-making and health-related quality of life. 

American Society of Hematology
2022

Cancer patients and survivors experience distress related to physical, psychological, social, and financial concerns. Individuals diagnosed with triple negative breast cancer(TNBC) may be at increased risk of distress due to the aggressive nature of the illness and high rates of recurrence.

San Antonio Breast Cancer Symposium
2022

Individuals with triple negative breast cancer (TNBC) are at increased risk for financial toxicity, which can negatively impact treatment adherence and health-related quality of life.

San Antonio Breast Cancer Symposium
2022

Myelodysplastic syndromes (MDS) are particularly costly, with patients facing an estimated burden of nearly $130,000 in the first two years following diagnosis.

American Society of Hematology
2022

About 1 in 5 people diagnosed with breast cancer (BC) will be considered HER2+, and nearly half of those diagnosed with HER2+ BC develop brain metastases. Brain metastases increase the risk of impairments, faster disease progression, and shorter survival time. Despite the significant burden faced by people with HER2+ BC living with brain metastases (BMBC), there is little research available characterizing the unique experiences of this community.

San Antonio Breast Cancer Symposium
2022